Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer;A cisplatin okozta nefrotoxicitás elofordulása, kockázati tényezoi és megelozése tüdokarcinómás betegekben

Magyar Onkologia

Volumn 54, Issue 4, 2010, Pages 289-296

  Losonczy, György ^a   Máthé, Csaba ^a   Müller, Veronika ^a   Szondy, Klára ^a   Moldvay, Judit ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

cisplatin; creatinine clearance; lung cancer; nephrotoxicity; salt diuresis

Indexed keywords

CISPLATIN; CREATININE; SODIUM CHLORIDE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG MEGADOSE; HUMAN; INCIDENCE; KIDNEY FUNCTION; LUNG CANCER; NEPHROTOXICITY; REVIEW; RISK FACTOR; SALURESIS;

ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CISPLATIN; COMORBIDITY; CREATININE; DIABETES COMPLICATIONS; EUROPE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; KIDNEY; KIDNEY FUNCTION TESTS; LUNG NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 79951886061     PISSN: 00250244     EISSN: 20600399     Source Type: Journal    
DOI: 10.1556/MOnkol.54.2010.4.3     Document Type: Review

References (35)

1. Aapro M, Launay-Vacher V, Lichtman S, et al. Areport from a SIOG Task Force on Renal Safety in the Elderly. SIOG Newsletter 1, 2005
2. Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep 66:31-35, 1982 (Pubitemid 12254661)
3. Bálint P. Az orvosi élettan tankönyve. Medicina, 1974
4. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982 (Pubitemid 12049914)
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
6. Cohen SH, Abesamis C, Zangi I, et al. Body elemental composition: comparison between black and while adults. Am J Physiol 232: E119-E122, 1977
7. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-298, 1977 (Pubitemid 8177356)
8. Garg AX, Papaioannou A, Ferko N, et al. Estimating the prevalence of renal insufficiency in seniors requiring long-term care. Kidney Int 65:649-653, 2004 (Pubitemid 38130661)
9. Greenfeld Z, Baylis C. Aging and the renal circulation. In: Advances in Organ Biology, Vol. 9. JAI Press, 2000, pp. 255-274
10. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cisplatinium diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 39:1372-1381,1977 (Pubitemid 8108287)
11. Heidemann HTH, Gerkens JF, Jackson EK, Branch RA. Attenuation of cisplatin induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide. Naunyn Schmiedebergs Arch Pharmacol 329:201-205, 1985 (Pubitemid 15078196)
12. Hill GS. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 17:266-270, 2008 (Pubitemid 351535929)
13. Howell S, Pfeifle C, Wung W, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97:845-851, 1982 (Pubitemid 13240565)
14. Hutchinson FN, Perez EA, Gandara DR, et al. Renal salt-wasting in patients treated with cisplatin. Ann Intern Med 108:21-25, 1988 (Pubitemid 18081164)
15. Launay-Vacher V, Chatelut E, Lichtman SM, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 18:1314-1321, 2007 (Pubitemid 47305003)
16. Launay-Vacher V, Etessami R, Janus N, et al (the Renal Insufficiency Anticancer Medications - IRMA - Study Group). Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 187:69-74, 2009
17. Launay-Vacher V, Izzedine H, Rey JB, et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 10: CR209-CR212, 2004
18. Launay-Vacher V, Rey JB, Isnard-Bagnis C, et al. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61:903-909, 2008
19. Lehane D, Winston A, Gray R, Daskal Y. The effect of diuretic pretreatment on clinical morphological and ultrastructural cis-platinium induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5:1393-1399, 1979 (Pubitemid 10159446)
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999 (Pubitemid 29135798)
21. Levey AS, Eckhardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67:2089-2100, 2005 (Pubitemid 41623371)
22. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:155A (Abstr. 0828), 2000
23. Madias NE, Harrington JT. Platinium nephrotoxicity. Am J Med 65:307-314, 1978
24. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockcroft- Gault, Jelliffe and Wright formulas in estimating renal function in elderly patients. Ann Oncol 15:291-295, 2004
25. Máthé C, Bohács A, Duffek L, et al. Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients. Eur Respir J erj00551-2010, Epub ahead of print
26. Ozols RF, Ostchega Y, Myers CF, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 3:1246-1250, 1985 (Pubitemid 15226530)
27. Pera MF Jr, Zook BC, Harder HC. Effect of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cisdichlorodiammine platinum (II) in rats. Cancer Res 29:1269-1278, 1979 (Pubitemid 9183844)
28. Perkins BA, Krolewski AS. Early nephropathy in type I diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 18:233-240, 2009
29. Ries L, Kosary C, Hankey B (eds.). SEER Cancer Statistics Review, 1975-1995. National Cancer Institute, National Institutes of Health. Bethesda, MD, 1998
30. Santoso JT, Lucci JA 3rd, Coleman RL, et al. Saline, mannitol and furosemide hydration in acute cisplatin nephrotoxicity. A randomized trial. Cancer Chemother Pharmacol 52:13-18, 2003 (Pubitemid 36920623)
31. Swedko PJ, Clark HD, Paramsothy K, Akbari A. serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 163:356-360, 2003 (Pubitemid 36183865)
32. Thomas F, Seronie-Vivien S, Gladieff L, et al. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet 44:1305-1316, 2005 (Pubitemid 41832571)
33. Verhave JC, Fesler P, Ribstein J, et al. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 46:233-241, 2005 (Pubitemid 41040351)
34. Yamamoto K, Shimokawa T, Yi H, et al. Aging accelerates endotoxin- induced thrombosis: increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol 161:1805-1814, 2002
35. Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14:17-23, 2000